Efficacy of Pioglitazone and Insulin in Treating Subjects With Type 2 Diabetes Mellitus and Renal Failure.

Inclusion Criteria: * Has Type 2 Diabetes Mellitus, and is a patient on insulin treatment for at least 3 months. * Has a body mass index less than 36 kg/m² * Has a glycosylated hemoglobin level greater than or equal to 6.0% and less than 10%. * Patient is on hemo-dialysis with or without residual excretion * An insulin dose greater than 20 IE/day Exclusion Criteria: * Has a history of type 1 diabetes. * Has acute infections. * History of hypersensitivity to the study drugs or to drugs with similar chemical structures. * History of severe or multiple allergies. * Has a progressive fatal disease other than kidney failure. * Has a history of drug or alcohol abuse within the last 5 years. * A history of significant cardiovascular (e.g. Coronary heart failure based on New York Heart Association stage III - IV), respiratory, gastrointestinal, hepatic (e.g. alanine aminotransferase greater than 2.5 times the normal reference range) or hematological disease. * History of primary hyperaldosteronism * Acute myocardial infarction, open heart surgery or cerebral event (stroke/transient ischemic attack) within the last year prior to study start. * Any further antidiabetic treatment except pioglitazone and insulin. * History of macular edema. * Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including: * Treatment with any other investigational drug within 3 months before trial entry. * Treatment with steroids within 3 months before trial entry. * Treatment with thiazolidinediones within the past 3 months. * If statin therapy applicable: Change of medication within the last 4 weeks. * Pre-treatment with gemfibrozil within the last 12 weeks. * Pre-treatment with rifampicin within the last 12 weeks. * Has uncontrolled unstable angina.